Fintel on MSN1d
JMP Securities Downgrades Syros Pharmaceuticals (SYRS)
Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...
Hosted on MSN1d
TD Cowen Downgrades Syros Pharmaceuticals (SYRS)
Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...
Business Insider1d
Syros Pharmaceuticals downgraded to Hold from Buy at Brookline
Brookline downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot ...
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure
Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.
JMP Securities downgrades Syros Pharmaceuticals (SYRS) to a Hold
Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.